Saturday 17 October 2026 Export QTTB’s income statement to Excel — free account

Q32 Bio Inc.

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.52 0.25 −3.22%

Follow QTTB

Alert me

Market cap: $231.3M
P/E: 2.5×
Fwd P/E: −7.2×
Dividend yield: —
F-score: n/a
Altman Z: −0.78
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 30.00

Total sells 0.51

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	2	—	—	—	—	—
Sell	—	2	—	3	—	—	—	—	—	3	—	3

Insider Ownership 5.42%

Capital & Financial Ratios $m

Market Cap 231.31

Revenue (6.65)

Net Income 33.79

Free Cash Flow (19.83)

Net Debt (106.27)

Current Ratio 20.30

Debt/Equity 0.00

P/E ratio 2.49

Fwd P/E (7.22)

P/S ratio 0.00

P/B ratio 1.44

Past 5Y EPS Growth —

This Y EPS Growth (161.21%)

Next Y EPS Growth (47.98%)

Next Y revenue growth (99.38%)

Next 5Y EPS Growth 9.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 34.41%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	26	78	48	106
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	29	82	55	110

	2023	2024	2025	Q'26
Payables	3	3	1	2
ST’ Debt	1	3	6	—
Other	—	3	—	—
	14	16	11	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	100.32%	16.52%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(26.51%)	(38.20%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	54
’23	3	3	2	(15)	(7)
’22	1	1	1	1	3
’21	29	2	2	1	34
’20	1	1	1	1	3
’19	0	0	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(12)	(11)	(4)	(6)	(34)
’24	(15)	(22)	(20)	(11)	(68)
’23	(12)	(11)	16	(11)	(19)
’22	(31)	(31)	(25)	(27)	(114)
’21	(30)	(24)	(25)	(30)	(110)
’20	(26)	(28)	(29)	(12)	(94)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(12)	(11)	(4)	1	(27)
’24	(15)	(22)	(20)	(11)	(68)
’23	(13)	(11)	16	(11)	(19)
’22	(32)	(31)	(25)	(27)	(115)
’21	(31)	(25)	(26)	(31)	(112)
’20	(28)	(29)	(29)	(13)	(98)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.54)	(0.44)	—	—	—
’25	(0.90)	(0.78)	(0.60)	4.58	2.42
’24	0.44	(1.42)	(1.46)	(1.16)	(4.94)
’23	(19.84)	(16.69)	(40.52)	(76.91)	(153.96)
’22	28.60	(9.17)	(10.61)	(10.79)	(1.62)
’21	(0.36)	(9.71)	(9.71)	(10.61)	(31.11)
’20	(14.03)	(14.03)	(11.15)	(11.15)	(50.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	271.26	198.90	156.60	64.98	18.72	8.24	3.02	1.35	Analyst estimates 2026–2028 Powerpack
	High	—	—	477.00	572.40	402.84	274.32	76.68	31.68	53.79	6.37
People
People	Employees	—	67	124	187	205	224	92	7	42	24
	Revenue/emp, $m	—	0.00	0.04	0.01	0.01	0.15	0.03	(0.95)	0.00	2.24
Income, $m
Income, $m	Revenue	—	—	5	2	3	34	3	(7)	—	54
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	—	100.00
	EBT	(8)	(30)	(56)	(104)	(129)	(96)	1	(53)	(46)	30
	EBT margin, %	0.00	0.00	(1,044.29)	(6,237.45)	(4,762.92)	(281.90)	37.34	803.26	0.00	55.49
	Net income	(8)	(30)	(56)	(104)	(129)	(96)	(5)	(54)	(48)	30
	Depreciation	0	1	1	6	8	9	(1)	1	0	1
Per share, $
Per share, $	Revenue	0.00	0.00	3.35	0.71	1.06	11.05	1.01	(19.05)	0.00	4.37
	Earnings	(76.13)	(217.59)	(35.97)	(44.42)	(50.36)	(31.11)	(1.62)	(153.96)	(5.12)	2.42
	Cash flow	(80.27)	47.02	(26.81)	(39.01)	(36.96)	(35.71)	(35.61)	(53.50)	(7.26)	(2.73)
	Capex	(18.82)	(14.21)	(15.71)	(9.32)	(1.46)	(0.78)	(0.40)	(0.01)	(0.01)	0.57
	Free cash flow	(99.09)	32.81	(42.52)	(48.33)	(38.42)	(36.48)	(36.02)	(53.51)	(7.27)	(2.16)
	Book value	70.96	713.41	123.69	110.39	76.78	55.19	55.77	(204.74)	0.61	3.42
	Shares, m	0	0	2	2	3	3	3	0	9	12
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	—	1.43
	P/S	—	—	120.06	523.74	191.98	5.93	21.49	0.00	—	0.00
	P/B	—	—	3.25	3.38	2.65	1.19	0.39	0.00	—	0.97
	EV/Sales	—	—	79.71	366.25	117.23	2.04	(23.88)	(3.34)	—	(0.34)
	EV/FCF	—	—	(6.28)	(5.39)	(3.23)	(0.62)	0.67	(1.19)	—	(0.08)
Cash, $m
Cash, $m	Operating cash flow	(8)	6	(43)	(91)	(94)	(110)	(114)	(19)	(68)	(34)
	Capex	(2)	(2)	(25)	(22)	(4)	(2)	(1)	0	0	7
	Free cash flow	(10)	5	(68)	(113)	(98)	(112)	(115)	(19)	(68)	(27)
Balance, $m
Balance, $m	Working capital	6	123	199	254	197	175	158	15	65	44
	Total debt	—	—	—	—	15	24	29	44	13	10
	Net debt	(11)	(130)	(215)	(262)	(202)	(132)	(146)	18	(65)	(39)
	Shareholders’ equity	8	98	196	259	196	170	178	(71)	6	42
Returns, %
Returns, %	ROA	(10.61)	(39.53)	(28.03)	(36.48)	(44.82)	(40.28)	(2.27)	(39.01)	(68.49)	38.70
	ROIC	0.00	0.00	0.00	0.00	0.00	(159.02)	(256.87)	0.00	0.00	308.43
	ROE	32.61	121.55	(70.84)	(45.69)	(56.63)	(52.38)	(2.88)	2,174.51	53.86	125.06

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BBOT BridgeBio Oncology Therapeutics, Inc	$236.5M	— (loss-making)	—	—	n/m	−88.78% (below 0%: shrinking)	—	0.00%	Compare
SABS SAB Biotherapeutics, Inc.	$235.7M	— (loss-making)	19.9×	−90.95% (below 0%: shrinking)	n/m	−59.75% (below 0%: shrinking)	100.00%	0.00%	Compare
IMRX Immuneering Corporation	$235.5M	— (loss-making)	— (loss-making)	−99.74% (below 0%: shrinking)	n/m	−74.94% (below 0%: shrinking)	0.00%	0.00%	Compare
QTTB Q32 Bio Inc.	$231.3M	2.5×	— (loss-making)	−1,928.18% (below 0%: shrinking)	n/m	+71.13% (above 0%: growing)	100.00%	0.00%
FATE Fate Therapeutics, Inc.	$230.7M	— (loss-making)	— (loss-making)	+9.18% (above 0%: growing)	n/m	+8.96% (above 0%: growing)	100.00%	(1,495.39%)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
SLGL Sol-Gel Technologies Ltd.	$224.9M	— (loss-making)	— (loss-making)	−96.58% (below 0%: shrinking)	n/m	−8.76% (below 0%: shrinking)	100.00%	(704.23%)	Compare
GLSI Greenwich LifeSciences, Inc.	$224.9M	— (loss-making)	—	—	n/m	+13.14% (above 0%: growing)	0.00%	0.00%	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$228.6M	—	—	−96.58%	—	+0.10%	100.00%	0.00%

All 614 Biotechnology stocks →

Q32 Bio Inc. (QTTB) key facts

Q32 Bio Inc. (QTTB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.
As of October 16, 2026, QTTB traded at $7.52, a market capitalization of $231.3 million.
Return on equity was 125.1% and debt-to-equity 0.00.
Its Altman Z-score is −0.78 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.